Tom 14, Nr 5 (2019)
Artykuł przeglądowy
Opublikowany online: 2019-07-02
Wyświetlenia strony
873
Wyświetlenia/pobrania artykułu
2152
Kwas acetylosalicylowy AD 2019 — znane zalety, nowe wyzwania
Folia Cardiologica 2019;14(5):467-474.
Streszczenie
W niniejszym opracowaniu podsumowano aktualne zalecenia dotyczące właściwości przeciwpłytkowych oraz wskazań do profilaktycznego stosowania małych dawek kwasu acetylosalicylowego (ASA). Omówiono wyniki najnowszych badań dotyczących przede wszystkim prewencji pierwotnej, optymalnego dawkowania w kontekście zagadnienia aspirynooporności oraz możliwości poprawy długoterminowej współpracy pacjentów wymagających stosowania ASA. Omówiono również sposoby zapobiegania stosunkowo częstemu problemowi nietolerancji leku ze strony przewodu pokarmowego.
Słowa kluczowe: ASAmiażdżycafarmakoterapiachoroba niedokrwiennabezpieczeństwo
Referencje
- WHO model list of essential medicines. 20th list, amended August 2017. http://www.who.int/medicines/publications/essentialmedicines/en/.
- Lotrionte M, Biasucci LM, Peruzzi M, et al. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis. Prog Cardiovasc Dis. 2016; 58(5): 495–504.
- Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018; 392(10145): 387–399.
- Piepoli M, Hoes A, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016; 37(29): 2315–2381.
- Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849–1860.
- Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39: 213–260.
- Mahmoud AN, Gad MM, Elgendy AY, et al. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019; 40(7): 607–617.
- Bibbins-Domingo K. U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164(12): 836–845.
- Bowman L, Mafham M, Wallendszus K, et al. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018; 379(16): 1529–1539.
- Gaziano JM, Brotons C, Coppolecchia R, et al. ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018; 392(10152): 1036–1046.
- McNeil JJ, Woods RL, Nelson MR, et al. ASPREE Investigator Group, ASPREE Investigator Group. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018; 379(16): 1519–1528.
- Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994; 25(12): 2331–2336.
- Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003; 41(6): 961–965.
- Dominiak M, Wcisło T, Krzemińska-Pakuła M, et al. Predictors of successful acetylsalicylic acid resistance suppression after percutaneous coronary revascularisation. Kardiol Pol. 2013; 71(12): 1229–1236.
- Neubauer H, Kaiser AFC, Endres HG, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011; 9: 3.
- Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940–2948.
- Moberg C, Naesdal J, Svedberg LE, et al. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk. Patient. 2011; 4(2): 103–113.
- Bhatt DL, Grosser T, Dong JF, et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017; 69(6): 603–612.
- Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013; 127(3): 377–385.
- Murtaza G, Karim S, Najam-ul-Haq M, et al. Interaction analysis of aspirin with selective amino acids. Acta Pol Pharm. 2014; 71(1): 139–143.
- Müller P, Dammann HG, Bergdolt H, et al. [The effect of glycine on the gastroduodenal tolerability of acetylsalicylic acid. An endoscopic, controlled double-blind study in healthy subjects]. Arzneimittelforschung. 1991; 41(8): 812–814.
- Kusche W, Paxinos R, Haselmann J, et al. Acetylsalicylic acid tablets with glycine improve long-term tolerability in antiplatelet drug therapy: results of a noninterventional trial. Adv Ther. 2003; 20(5): 237–245.
